The Termeer Foundation
U M

Tinashe Chandauka

Nandi creates biotech companies that address rare, oncology and auto-immune disorders.

 

Tinashe Chandauka

Nandi creates biotech companies that address rare, oncology and auto-immune disorders.

CLASS OF 2024

COMPANY

Nandi Life Sciences
Founder & CEO

LOCATION

Houston, TX

AREA OF FOCUS

Oncology, auto-immune, rare diseases

BIO

Dr. Tinashe Chandauka is Co-Founder and CEO of Nandi Life Sciences which is a rare disease, oncology and auto-immune biotechnology company. Nandi is currently developing two assets: an asset targeting adaptive resistance to anti-angiogenic drugs in solid tumors and another targeting an autoimmune endocrine disorder. He is an Entrepreneur-in-Residence at Texas Medical Center Innovation’s Accelerating Cancer Therapeutics (ACT), an initiative funded by the Texas government’s US$6B Cancer Prevention & Research Institute of Texas.

Prior to this, he was the Director of Early Pipeline Development at NASDAQ listed Tarsus Pharmaceuticals. Before this, he was at Oxford Science Enterprises (OSE) where he participated in over $350M of early-stage venture capital investments, supported the growth and financing 55 early stage companies and supported the $160M Series B fundraise and preparations for the NASDAQ IPO of Vaccitech, inventor of the Oxford COVID-19 vaccine as a founding member of the OSE portfolio management team.

He holds a PhD from Oxford University where he was a Rhodes Scholar and a medical degree from the University of Cape Town, with distinction and honours. He holds medical practice licences in the United Kingdom and South Africa. He is a member of the board of directors of AMREF, a global Africa focused healthcare charity.

View all current fellows